ClinicalTrials.gg
CompletedNCT00179660Updated Jan 21, 2016Results posted

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

A Phase 2 interventional study of Lenalidomide in Non-Hodgkins Lymphoma, sponsored by Celgene Corporation. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-01-21.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin — 2 open to participants now, 4 under way, 1 of them phase 3. Lenalidomide · Lymphoma, Non-Hodgkin.

Enrollment
14th of 31
50 · median 46
Started
2005
with 1 other
Phase 2
11 of 32
1 open now
Registered
3rd of 32
by date
Lead sponsor
2 of 32
Celgene Corporation

Among the 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin, this one is the 14th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2005, is one of 11 in phase 2, and was the 3rd registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

2 of the 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

To determine the activity of lenalidomide in relapsed or refractory aggressive NHL.

03

Conditions studied

  • Non-Hodgkins Lymphoma

Keywords

  • celgene
  • cc-5013
  • CC5013
  • NHL
  • Non-Hodgkins Lymphoma
  • Revlimid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Understand and voluntarily sign an form.
  2. Age greater than or equal to 18 years at the time of signing the informed consent form
  3. Able to adhere to the study visit schedule and other protocol requirements
  4. -proven non-Hodgkin's lymphoma
  5. Aggressive lymphoma, the following histologies are acceptable: Follicular center lymphoma, grade 3, Diffuse large cell, Mantle cell, Transformed
  6. to previous therapy for lymphoma. Patients must have received at least one prior treatment regimen such as radiation, immunotherapy, chemotherapy, or radioimmunotherapy, and be ineligible or unwilling to undergo an stem cell transplant. There is no limit on the number of prior therapies.
  7. Patients must have on cross sectional imaging that is at least 2 cm in the longest diameter.
  8. (ECOG) performance status score of 0, 1 or 2.
  9. Women of (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug. In addition, sexually active WCBP must agree to use adequate methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug.

Exclusion criteria

Exclusion Criteria:

  1. Any of the following laboratory abnormalities:

    1. (ANC) \<1,500 cells/mm\^3 (1.5 x 10\^9/L)
    2. count \<100,000/mm\^3 (100 x 10\^9/L)
    3. Serum creatinine >2.5 mg/dL (221 mmol/L)
    4. Serum (AST) or alanine transaminase (ALT) >5.0 x (ULN)
    5. Serum total >2.0 mg/dL (34 mmol/L)
  2. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  3. All patients with central nervous system (CNS) disease with the exception of those patients whose CNS disease has been treated with chemotherapy, radiotherapy or surgery and remains asymptomatic, with no active CNS disease, as shown by lumbar puncture, computed tomography (CT) scan or magnetic resonance imaging (MRI), for at least 6 months.
  4. Prior history of other than non-Hodgkin's lymphoma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for > or equal to 1 year
  5. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the form
  6. Known positive for (HIV)
  7. Pregnant or lactating females
  8. Prior > or equal to grade 3 National Cancer Institute (NCI CTCAE) allergic reaction/ to thalidomide
  9. Prior > or equal to grade 3 NCI CTCAE rash or any desquamating (blistering) rash while taking thalidomide
  10. Prior use of lenalidomide
  11. Use of any standard or experimental anti-cancer drug therapy within 28 days of day 1 of study drug therapy
  12. Known active
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Lenalidomide

    Participants received single-agent lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed, lenalidomide treatment was discontinued for any reason, or the study was terminated.

    Drug: Lenalidomide

Interventions

  • Capsules for oral administration.

    Also known as: CC-5013, Revlimid®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Response

    Response was defined as participants with a complete response (CR), unconfirmed complete response (Cru) or partial response (PR), assessed using the International Workshop Lymphoma Response Criteria (IWLRC) and based on best responses as determined by the investigator. CR: Complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities. Cru: Criteria for CR above but with 1 or more of the following: * A residual lymph node mass \> 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of diameters (SPD) * Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia). PR: 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD.

    Time frame: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.

Secondary outcomes

  1. Percentage of Participants With Tumor Control

    Tumor control was defined as participants with a complete response, unconfirmed complete response, partial response or stable disease (SD), assessed using the International Workshop Lymphoma Response Criteria (IWLRC) and based on best responses as determined by the investigator. SD was defined as a response less than a PR (see above) but not Progressive Disease (PD). PD was defined as * ≥ 50 % increase from nadir in the SPD of any previously identified abnormal node for partial responders or non-responders. * Appearance of any new lesion during or at the end of therapy.

    Time frame: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.

  2. Duration of Response

    The duration of response was calculated as the first response assessment demonstrating evidence of at least a partial response to the first documentation of progressive disease (as determined by computed tomography scan) or death due to NHL, whichever occurred first. For participants without documentation of progression, the duration of response was censored at the last date of tumor assessment indicating no progression. Median was based on the Kaplan-Meier estimate.

    Time frame: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.

  3. Duration of Tumor Control

    The duration of tumor control was calculated as the time from the first response assessment demonstrating at least stable disease to the first documentation of progressive disease or death due to NHL. For participants without documentation of progression, the duration of response was censored at the last date of tumor assessment indicating no progression. Median was based on the Kaplan-Meier estimate.

    Time frame: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.

  4. Progression-free Survival

    Progression-free survival was defined as the time from the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever came first. Participants who withdrew for any reason or received another NHL therapy including stem cell transplantation without documented progressive disease were censored on the date of their last adequate response assessment indicating no progression (or last adequate assessment prior to receiving other NHL therapy). Participants who were still active without progressive disease at the time of the data cut-off date were censored on the date of their last adequate response assessment.

    Time frame: From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.

  5. Number of Participants With Adverse Events (AEs)

    The Investigator determined the relationship between the administration of study drug and the occurrence of an AE as suspected if the temporal relationship of the adverse event to study drug administration made a causal relationship possible, and other drugs, therapeutic interventions, or underlying conditions did not provide a sufficient explanation for the observed event. The Investigator graded the severity of AEs according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) criteria and the following scale: * Grade 1 = Mild * Grade 2 = Moderate * Grade 3 = Severe * Grade 4 = Life threatening * Grade 5 = Death A Serious AE is defined as any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or constitutes an important medical event.

    Time frame: From the start of study drug through 30 days after the last dose of study drug. Maximum time on study drug was 15.2 months.

07

Results

Posted Sep 2, 2013

Participant flow

Participant flow — Overall Study
MilestoneLenalidomide
Started50
Received study drug49
Completed 12 cycles of treatment12
Completed0
Not completed50
Withdrew: Adverse event7
Withdrew: Lack of therapeutic effect28
Withdrew: Withdrawal by subject2
Withdrew: Lost to follow-up1
Withdrew: Death3
Withdrew: Other - unspecified9

Outcome measures

PrimaryPercentage of Participants With Response

Response was defined as participants with a complete response (CR), unconfirmed complete response (Cru) or partial response (PR), assessed using the International Workshop Lymphoma Response Criteria (IWLRC) and based on best responses as determined by the investigator. CR: Complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities. Cru: Criteria for CR above but with 1 or more of the following: * A residual lymph node mass \> 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of diameters (SPD) * Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia). PR: 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD.

Time frame:
From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
Reported as:
Number · percentage of participants
Percentage of Participants With Response
percentage of participantsLenalidomide
Percentage of Participants With Response34.7 (21.7 to 49.6)
SecondaryPercentage of Participants With Tumor Control

Tumor control was defined as participants with a complete response, unconfirmed complete response, partial response or stable disease (SD), assessed using the International Workshop Lymphoma Response Criteria (IWLRC) and based on best responses as determined by the investigator. SD was defined as a response less than a PR (see above) but not Progressive Disease (PD). PD was defined as * ≥ 50 % increase from nadir in the SPD of any previously identified abnormal node for partial responders or non-responders. * Appearance of any new lesion during or at the end of therapy.

Time frame:
From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
Reported as:
Number · percentage of participants
Percentage of Participants With Tumor Control
percentage of participantsLenalidomide
Percentage of Participants With Tumor Control59.2 (44.2 to 73.0)
SecondaryDuration of Response

The duration of response was calculated as the first response assessment demonstrating evidence of at least a partial response to the first documentation of progressive disease (as determined by computed tomography scan) or death due to NHL, whichever occurred first. For participants without documentation of progression, the duration of response was censored at the last date of tumor assessment indicating no progression. Median was based on the Kaplan-Meier estimate.

Time frame:
From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
Reported as:
Median · months
Duration of Response
monthsLenalidomide
Duration of Response10.2 (4.0 to 16.3)
SecondaryDuration of Tumor Control

The duration of tumor control was calculated as the time from the first response assessment demonstrating at least stable disease to the first documentation of progressive disease or death due to NHL. For participants without documentation of progression, the duration of response was censored at the last date of tumor assessment indicating no progression. Median was based on the Kaplan-Meier estimate.

Time frame:
From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
Reported as:
Median · months
Duration of Tumor Control
monthsLenalidomide
Duration of Tumor Control6.0 (2.9 to 11.1)
SecondaryProgression-free Survival

Progression-free survival was defined as the time from the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever came first. Participants who withdrew for any reason or received another NHL therapy including stem cell transplantation without documented progressive disease were censored on the date of their last adequate response assessment indicating no progression (or last adequate assessment prior to receiving other NHL therapy). Participants who were still active without progressive disease at the time of the data cut-off date were censored on the date of their last adequate response assessment.

Time frame:
From enrollment through study completion. Median duration on study was 3.7 months, with a maximum of 32.5 months.
Reported as:
Median · months
Progression-free Survival
monthsLenalidomide
Progression-free Survival3.6 (2.0 to 6.3)
SecondaryNumber of Participants With Adverse Events (AEs)

The Investigator determined the relationship between the administration of study drug and the occurrence of an AE as suspected if the temporal relationship of the adverse event to study drug administration made a causal relationship possible, and other drugs, therapeutic interventions, or underlying conditions did not provide a sufficient explanation for the observed event. The Investigator graded the severity of AEs according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) criteria and the following scale: * Grade 1 = Mild * Grade 2 = Moderate * Grade 3 = Severe * Grade 4 = Life threatening * Grade 5 = Death A Serious AE is defined as any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or constitutes an important medical event.

Time frame:
From the start of study drug through 30 days after the last dose of study drug. Maximum time on study drug was 15.2 months.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsLenalidomide
Any adverse event49
Adverse event related to study drug42
Grade 3-5 adverse event36
Grade 3-5 adverse event related to study drug27
Serious adverse event21
Serious adverse event related to study drug6
AE leading to discontinuation of study drug9
Related AE leading to study drug discontinuation4
AE leading to dose reduction or interruption28

Adverse events

Collected over From the start of study drug through 30 days after the last dose of study drug. Maximum time on study drug was 15.2 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide—21/49 (42.9%)48/49 (98%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventLenalidomide
Non-Hodgkin's lymphoma NOSNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/49
PyrexiaGeneral disorders3/49
Pneumonia NOSInfections and infestations3/49
Febrile neutropeniaBlood and lymphatic system disorders2/49
ThrombocytopeniaBlood and lymphatic system disorders2/49
Dyspnea NOSRespiratory, thoracic and mediastinal disorders2/49
Anemia NOSBlood and lymphatic system disorders1/49
Coombs positive hemolytic anemiaBlood and lymphatic system disorders1/49
Acute myocardial infarctionCardiac disorders1/49
Cardiac failure congestiveCardiac disorders1/49
Most frequent other events
Showing 10 of 52
Most frequent other events
EventLenalidomide
FatigueGeneral disorders19/49
NeutropeniaBlood and lymphatic system disorders19/49
ThrombocytopeniaBlood and lymphatic system disorders18/49
ConstipationGastrointestinal disorders15/49
Anaemia NOSBlood and lymphatic system disorders15/49
Rash NOSSkin and subcutaneous tissue disorders13/49
Diarrhoea NOSGastrointestinal disorders12/49
Platelet Count DecreasedInvestigations11/49
NauseaGastrointestinal disorders10/49
CoughRespiratory, thoracic and mediastinal disorders10/49

Baseline characteristics

Intent to treat population includes all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Lenalidomide
Mean64.8 ± 11.53
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide
Female24
Male25
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Lenalidomide
White36
Black2
Hispanic10
Asian/Pacific Islander1
Region of Enrollment
Region of Enrollment(participants)Lenalidomide
United States49
Eastern Cooperative Oncology Group (ECOG) performance status
Eastern Cooperative Oncology Group (ECOG) performance status(participants)Lenalidomide
020
123
25
Missing1
Non-Hodgkin's Lymphoma (NHL) Stage
Non-Hodgkin's Lymphoma (NHL) Stage(participants)Lenalidomide
Stage I1
Stage II7
Stage III9
Stage IV32
NHL histology
NHL histology(participants)Lenalidomide
Follicular lymphoma grade 35
Diffuse large B-cell lymphoma26
Mantle cell lymphoma15
Transformed3
NHL Duration
NHL Duration(years)Lenalidomide
Mean4.0 ± 4.91

1 further baseline measures are reported on the registry.

08

Study locations

8 sites
  • Mayo Clinic Scottsdale
    Scottsdale, Arizona 85259, United States
  • Pacific Coast Hematology/Oncology Medical Group, Onc.
    Fountain Valley, California 92708, United States
  • UC David Cancer Center
    Sacramento, California 95817, United States
  • Sylvester Cancer CenterUniversity Of Miami
    Miami, Florida 33136, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Nebraska
    Omaha, Nebraska 68198-6805, United States
  • New York Medical Center, MBCCOP
    Bronx, New York 10466, United States
  • Gunderson Clinic, Ltd
    La Crosse, Wisconsin 54601, United States
09

References and documents

Publications

  • Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008 Oct 20;26(30):4952-7. doi: 10.1200/JCO.2007.15.3429. Epub 2008 Jul 7. PubMed 18606983 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2005, a primary completion of Jun 2008 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 5 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 16, 2005
Start
Aug 2005
Primary completionActual
Jun 2008
CompletionActual
Jun 2008
Results first posted
Sep 2, 2013
Last update
Jan 21, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00179660
Collaborators
Prologue Research International
Responsible party
Sponsor
First posted
Sep 16, 2005
Start date
Aug 2005
Primary completion
Jun 2008
Completion
Jun 2008
Results posted
Sep 2, 2013
Last update
Jan 21, 2016
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion